1-isopropyl-1H-indole-4-carboxylic acid | 1030423-99-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-isopropyl-1H-indole-4-carboxylic acid
• 英文别名: 1-(propan-2-yl)-1H-indole-4-carboxylic acid；1-propan-2-ylindole-4-carboxylic acid
• CAS: 1030423-99-4
• 化学式: C₁₂H₁₃NO₂
• mdl: MFCD15200972
• 分子量: 203.241
• InChiKey: BULZKWRARUNZFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(aminomethyl)-6-methyl-4-propylpyridin-2(1H)-one hydrochloride 、 1-isopropyl-1H-indole-4-carboxylic acid 在 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以37%的产率得到1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide
  参考文献：
  名称：

  [EN] SUBSTITUTED BICYCLIC COMPOUNDS AS INHIBITORS OF EZH2
  [FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS UTILISÉS COMME INHIBITEURS D'EZH2

  摘要：

  本发明提供了公式1的化合物，其同位素形式、立体异构体或互变异构体，或其药用可接受的盐、溶剂化合物、N-氧化物、S-氧化物和多晶形式，以及其制备方法。本发明还涉及含有所述化合物的药物组合物，并其在治疗由EZH2（zeste同源物增强子2）介导的疾病或紊乱中的应用，特别是癌症。

  公开号：

  WO2014155301A1
• 作为产物：
  描述：

  4-氰基吲哚 在 sodium hydride 、 potassium hydroxide 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 1-isopropyl-1H-indole-4-carboxylic acid
  参考文献：
  名称：

  The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat

  摘要：

  Posttranslational methylation of histones plays a critical role in gene regulation. Misregulation of histone methylation can lead to oncogenic transformation. Enhancer of Zeste homologue 2 (EZH2) methylates histone 3 at lysine 27 (H3K27) and abnormal methylation of this site is found in many cancers. Tazemetostat, an EHZ2 inhibitor in clinical development, has shown activity in both preclinical models of cancer as well as in patients with lymphoma or INI1-deficient solid tumors. Herein we report the structure activity relationships from identification of an initial hit in a high-throughput screen through selection of tazemetostat for clinical development. The importance of several methyl groups to the potency of the inhibitors is highlighted as well as the importance of balancing pharmacokinetic properties with potency.

  DOI：

  10.1021/acs.jmedchem.5b01501

文献信息

• [EN] OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS<br/>[FR] OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES EN TANT QU'INHIBITEURS DE MAGL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2019134985A1

  公开（公告）日：2019-07-11

  The invention provides new heterocyclic compounds having the general formula (le), wherein R1, R1a and R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds. The compounds of formula (le) are monoacylglycerol lipase (MAGL) inhibitors, for use in the treatment of a variety of disorders.

  这项发明提供了具有一般式（Ie）的新杂环化合物，其中R1、R1a和R7如本文所述，包括这些化合物的组合物，制造这些化合物的方法以及使用这些化合物的方法。式（Ie）的化合物是单酰基甘油酶（MAGL）抑制剂，用于治疗各种疾病。
• [EN] INDOLES<br/>[FR] INDOLES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011140324A1

  公开（公告）日：2011-11-10

  herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.

  本文揭示了式(I)中吲哚的各种基团的定义，并且这些吲哚对治疗癌症有用。
• OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3737680A1

  公开（公告）日：2020-11-18
• [EN] SUBSTITUTED BICYCLIC COMPOUNDS AS INHIBITORS OF EZH2<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS UTILISÉS COMME INHIBITEURS D'EZH2
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2014155301A1

  公开（公告）日：2014-10-02

  The present invention provides compounds of formula 1, isotopic forms, stereoisomers or tautomers thereof, or pharmaceutically acceptable salts, solvates, N-oxides, S-oxides and polymorphs thereof, and processes for their preparation. The invention further relates to pharmaceutical compositions containing said compounds and their use in the treatment of diseases or disorders mediated by EZH2 (enhancer of zeste homolog 2), particularly cancer.

  本发明提供了公式1的化合物，其同位素形式、立体异构体或互变异构体，或其药用可接受的盐、溶剂化合物、N-氧化物、S-氧化物和多晶形式，以及其制备方法。本发明还涉及含有所述化合物的药物组合物，并其在治疗由EZH2（zeste同源物增强子2）介导的疾病或紊乱中的应用，特别是癌症。
• The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat
  作者：Kevin W. Kuntz、John E. Campbell、Heike Keilhack、Roy M. Pollock、Sarah K. Knutson、Margaret Porter-Scott、Victoria M. Richon、Chris J. Sneeringer、Tim J. Wigle、Christina J. Allain、Christina R. Majer、Mikel P. Moyer、Robert A. Copeland、Richard Chesworth

  DOI：10.1021/acs.jmedchem.5b01501

  日期：2016.2.25

  Posttranslational methylation of histones plays a critical role in gene regulation. Misregulation of histone methylation can lead to oncogenic transformation. Enhancer of Zeste homologue 2 (EZH2) methylates histone 3 at lysine 27 (H3K27) and abnormal methylation of this site is found in many cancers. Tazemetostat, an EHZ2 inhibitor in clinical development, has shown activity in both preclinical models of cancer as well as in patients with lymphoma or INI1-deficient solid tumors. Herein we report the structure activity relationships from identification of an initial hit in a high-throughput screen through selection of tazemetostat for clinical development. The importance of several methyl groups to the potency of the inhibitors is highlighted as well as the importance of balancing pharmacokinetic properties with potency.